Dublin, Sept. 25, 2017 -- The "Global Multiple Sclerosis Market: Patient Numbers & Forecast (By Mode of Administration: Injectables Market, Infusions Market, Orals Market) - Actual & Unmet (Potential)" report has been added to Research and Markets' offering.
Global multiple sclerosis market is steadily growing and it is expected to cross over US$ 20 Billion landmark by 2022
Multiple sclerosis market is one of the most common neurological disorder diseases in the world. It is estimated that global multiple sclerosis patient numbers will increase around 35 Thousand by 2022. According to analysis, we have found that there is huge gap between actual and unmet market as disease modifying therapy receiving prevalence vary from country to country. Global multiple sclerosis unmet market is much higher compared to its actual market.
Reimbursement is playing major role for the growth of multiple sclerosis market as multiple sclerosis drugs are too expensive and without reimbursement, it is nearly impossible to afford the treatment of MS by most of the multiple sclerosis patient in the world. Most of the European and North American countries have multiple sclerosis reimbursement policy; however eligibility criteria vary from country to country.
Multiple sclerosis drugs price is steadily increasing which create a major challenge for the growth of multiple sclerosis market in the world. It is estimated that newly launched multiple sclerosis drugs are expensive than previous generation disease modifying drugs. According to our research, we have found that, United States multiple sclerosis drugs are nearly five times higher than European multiple sclerosis drugs price.
Injectables Disease Modifying Therapy Multiple Sclerosis Market is losing Ground
Injectables disease modifying therapy multiple sclerosis market is continuously declining. Newly launched orals disease modifying therapy is a growing market.
Key Topics Covered:
1. Research Findings
2. Global Multiple Sclerosis Patient Numbers (2011 - 2022)
3. Global Multiple Sclerosis Market (2011 - 2022)
4. Patient Share - Global Multiple Sclerosis (2011 - 2022)
5. Market Share - Global Multiple Sclerosis (2011 - 2022)
6. United Kingdom
7. France
8. Germany
9. Italy
10. Spain
11. United States
12. Growth Drivers (Due to data confidentiality, growth factors have not been disclosed in this table of contents)
13. Challenges (Due to data confidentiality, challenges have not been disclosed in this table of contents)
For more information about this report visit https://www.researchandmarkets.com/research/56wqtx/global_multiple
CONTACT: Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Central Nervous System Drugs , Central Nervous System Drugs , Infusions and Injectables


Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment
Nintendo Shares Slide After Earnings Miss Raises Switch 2 Margin Concerns
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off
Nvidia Nears $20 Billion OpenAI Investment as AI Funding Race Intensifies
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO
Instagram Outage Disrupts Thousands of U.S. Users
Anthropic Eyes $350 Billion Valuation as AI Funding and Share Sale Accelerate
Australian Scandium Project Backed by Richard Friedland Poised to Support U.S. Critical Minerals Stockpile
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences 



